Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1145]
News [2517]
Articles [153]
Editorials [8]
Conferences [102]
elearning [18]
Novel class of drug for ovarian cancer
Dr Ronald Buckanovich - University of Michigan, Ann Arbor, USA
Novel class of drug for ovarian cancer ( Dr Ronald Buckanovich - University of Michigan, Ann Arbor, USA )
24 Nov 2011
Radium-223 in castration resistant prostate cancer
Dr Joaquim Bellumunt - Hospital del Mar, Barcelona, Spain
Radium-223 in castration resistant prostate cancer ( Dr Joaquim Bellumunt - Hospital del Mar, Barcelona, Spain )
21 Oct 2011
Review of prostate cancer at EMCC 2011
Dr Karim Fizazi - Institut Gustave Roussy, France
Review of prostate cancer at EMCC 2011 ( Dr Karim Fizazi - Institut Gustave Roussy, France )
21 Oct 2011
Treatment options for castration resistant prostate cancer
Dr Kurt Miller – University of Berlin, Germany
Treatment options for castration resistant prostate cancer ( Dr Kurt Miller – University of Berlin, Germany )
21 Oct 2011
Prostate cancer drug development update
Prof Cora Sternberg - San Camillo and Forlanini Hospitals, Rome, Italy
Prostate cancer drug development update ( Prof Cora Sternberg - San Camillo and Forlanini Hospitals, Rome, Italy )
21 Oct 2011
Radium 223 in the ALSYMPCA trial
Dr Chris Parker – Royal Marsden Cancer Centre, London, UK
Radium 223 in the ALSYMPCA trial ( Dr Chris Parker – Royal Marsden Cancer Centre, London, UK )
21 Oct 2011
Latest in renal carcinoma
Dr James Larkin - The Royal Marsden, London, UK
Latest in renal carcinoma ( Dr James Larkin - The Royal Marsden, London, UK )
21 Oct 2011
Evolving landscape in castration-resistant prostate cancer
Dr Per-Anders Abrahamsson - Lund University, Sweden; Dr Chris Parker - Royal...
Evolving landscape in castration-resistant prostate cancer ( Dr Per-Anders Abrahamsson - Lund University, Sweden; Dr Chris Parker - Royal Marsden Cancer Center, London, UK )
21 Oct 2011
Use of circulating tumour cells as a prognostic or predictive marker
Prof Caroline Dive - Paterson Institute for Cancer Research, Manchester, UK
Use of circulating tumour cells as a prognostic or predictive marker ( Prof Caroline Dive - Paterson Institute for Cancer Research, Manchester, UK )
20 Oct 2011
Roundup of the EMCC 2011 conference
Prof Gordon McVie - European Institute of Oncology and ecancer
Roundup of the EMCC 2011 conference ( Prof Gordon McVie - European Institute of Oncology and ecancer )
3 Oct 2011
Genetic mutations as causes of cancer
Dr Henry Lynch - Creighton University, Omaha, USA
Genetic mutations as causes of cancer ( Dr Henry Lynch - Creighton University, Omaha, USA )
25 Sep 2011
Phase III trial of an alpha-pharmaceutical
Dr Chris Parker - The Royal Marsden Cancer Centre, London, UK
Phase III trial of an alpha-pharmaceutical ( Dr Chris Parker - The Royal Marsden Cancer Centre, London, UK )
24 Sep 2011

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation